Feasibility of Using an LED-Probe in Third-Space Endoscopy: A Clinical Study

CURRENT STATUS: UNDER REVIEW

Oscar Victor Hernández Mondragón
Instituto Mexicano del Seguro Social
Corresponding Author
ORCiD: 0000-0002-7055-6210

Raul Antonio Zamarripa Mottu
Instituto Mexicano del Seguro Social

Omar Michell Solórzano Pineda
Instituto Mexicano del Seguro Social

Raul Antonio Gutierrez Aguilar
Instituto Mexicano del Seguro Social

Luis Fernando García Contreras
Instituto Mexicano del Seguro Social

DOI:
10.21203/rs.2.20562/v1

SUBJECT AREAS
Gastroenterology & Hepatology

KEYWORDS
third-space endoscopy, LED-probe, peroral endoscopic myotomy, gastric peroral endoscopic myotomy
Abstract

Background and aims: Third-space endoscopy is a novel, safe, and effective method for treating different gastrointestinal conditions. However, several failed endoscopic procedures are attributed to incomplete myotomy. Lighting devices are used to prevent organic injuries. We aimed to investigate the feasibility of using a hand-made LED-probe (LP) in third-space procedures.

Patients and Methods: This prospective study was conducted in a tertiary-care center in Mexico between December 2016 and January 2019. We included peroral endoscopic myotomy (POEM) and gastric peroral endoscopic myotomy (G-POEM) procedures. Pseudoachalasia, peptic ulcer, normal gastric emptying scintigraphy (GES) and prepyloric tumors were excluded. LP was used to guide or confirm procedures. Clinical and procedural characteristics were recorded and analyzed.

Results: Seventy third-space procedures were included (42POEM,28G-POEM), with an average patient age of 46.7±14.3 and 43.7±10.1 years, respectively. For the POEM and G-POEM groups, respectively, 18/42(42.9%) and 13/28(46.7%) patients were males, median procedure times were 50 (interquartile range[IQR]: 38-71) and 60(IQR: 48-77) min, median LP placement times were 5(IQR: 4-6) and 6(IQR: 5-7) min, mild adverse events occurred in 4(9.4%) and 4(14.2%) of cases, and clinical success at 6 months occurred in 100% and 85.7% of cases. Integrated relaxation pressure (IRP) improved from 27.3±10.8 to 9.5±4.1 mmHg (p<0.001); retention percentage at 4 hours also improved. LP was successfully placed and confirmed adequate myotomy including 14.2% and 17.8% of POEM and G-POEM difficult patients.

Conclusions: Using an LP is promising and allows guiding during third-space procedures either for submucosal tunnel creation or myotomy confirmation, with excellent safety and efficacy in clinical practice.
Background

Third-space endoscopy has emerged as a novel and effective method for the treatment of different gastrointestinal disorders such as achalasia and refractory gastroparesis [1-4]. However, difficult or incomplete myotomy has been identified in peroral endoscopy myotomy (POEM) and gastric-peroral endoscopy myotomy (G-POEM) as a result of different factors such as end-stage disease or previously treated cases (due to high submucosal fibrosis)[1, 5], inability to identify the esophagogastric junction (EGJ) throughout the submucosal tunnel during POEM[6-8] or the pyloric muscle ring (PMR) during G-POEM[9], lack of third-space endoscopy experience[2, 3, 6], and certain anatomical factors (megaesophagus, sigmoid-type)[4, 9, 10]. These factors are associated with a failed procedure. Different techniques, such as floroscopy [9, 11] or double endoscopy[12, 13] have been proposed to overcome these problems and guide an appropriate tunnel creation and myotomy; however, low availability and high costs limit their use.

Lighting devices for surgical guidance have been investigated for years with good results. In laparoscopic colorectal and gynecological surgeries, the use of lighted ureteral stents successfully prevented iatrogenic injuries [14, 15]. In ophthalmologic procedures, light-emitting diode (LED) technology is used for vitrectomy, with the advantage of no thermal or photodynamical harm; this provides better illumination than other light sources [16, 17]. In third-space endoscopy, the use of a dedicated LED-probe (LP) that could be inserted into the submucosal tunnel (cornerstone of the procedure) [1, 2, 8] could be used to guide the direction during the procedure or confirm a correct myotomy when combined with the endoscope, before closing the entry site. Use of an LP could be an excellent alternative during third-space endoscopic procedures. The aim of this study was to evaluate the feasibility of using of LP in clinical practice, especially during POEM or G-POEM third-space procedures.
Methods

Study design and ethical considerations

This prospective study was conducted in a tertiary care center in Mexico City, Mexico between December 2016 and January 2019. We included patients between the ages of 18 and 90 years with naïve or previously-treated achalasia or severe refractory gastroparesis and were treated with POEM or G-POEM, respectively, with 6 months of follow-up. Patients with pseudoachalasia were excluded from the POEM procedure. Active peptic ulcer disease, normal gastric emptying scintigraphy (GES) and prepyloric tumor lesions were excluded from G-POEM. Patients with severe clinical conditions that could be contraindications to any of these procedures were also excluded (severe chronic obstructive pulmonary disease, recent myocardial infarction). This protocol was approved by the Local Ethics Committee (R-2016-3601-192; registration number: 2016-CMN675). Informed consent was obtained from all patients.

POEM

Patients

The diagnosis of achalasia was based on the Chicago Classification [18], using high resolution manometry (HRM). Upper gastrointestinal (GI) endoscopy, computed tomography (CT) scanning, a timed barium esophagogram (TBE) and the Chagas disease test were performed. Esophageal classification was evaluated according to Rezende’s classification; [19] the Eckardt score was used for clinical evaluation[20].

Procedure

The esophagus was cleaned 24 hrs before the POEM procedure and antibiotic prophylaxis was administered. A 9.8-mm outer diameter with a 2.8-mm working channel endoscope was used (EG590WR; Fujinon, Tokyo, Japan), along with a transparent cap model (DH-
28GR, Fujinon). An electrosurgical unit (ERBE VIO-200D, Tübingen, Germany), and an I-type hybrid knife (ERBE, Tübingen, Germany) were also used. Closure was performed using hemoclips (Boston Scientific, Natick, Massachusetts, USA).

The LP system was created using a sterile polyurethane non-weighted 127 cm x 20 Fr nasogastric feeding tube (AMA proveduria, Mexico City, Mexico) that was cut at the middle. A thin strip of 150cms long of an ultrabright slim LED strip light system of 1/8 in [3.5 mm] in diameter, with a capability of 112 lm/m (FlexfireLEDs, Costa Mesa, California, USA), was inserted throughout this catheter and attached to it with one 127 cm long strip of Scotch black tape (3M, St. Paul, Minnesota, USA). This LP was coupled to a power supply system of 12 V that used conventional alkaline AA batteries (Duracell, Bethel, Connecticut, USA) (Video 1).

The POEM technique was based on Inoue’s technique [21]. The technique was performed using the following procedure: (1), initially, the esophagus was cleaned if necessary; (2), injection and incision were performed with a mixture of saline solution and 0.5% methylene blue being injected 13–15 cm above the EGJ (20 cm for type III patients) and a 12–15 mm longitudinal incision being made for anterior (naïve patients) or posterior (previously-treated patients) approaches; (3), the submucosal tunnel was created, with the tunnel being created up to 3 cm below the EGJ; (4), a full-thickness myotomy was performed in all patients; (5), the LP was placed through the mouth; once it passed the cricopharyngeal muscle, it was grasped using biopsy forceps under endoscopic visualization and inserted up to the end of the submucosal tunnel; (6), intraluminal revision of the POEM procedure was performed and EGJ was reviewed in retroflexion with the LP on, in order to confirm that submucosal tunnel reached gastric space and an adequate myotomy was performed. If LP on was not observed, submucosal tunnel and myotomy were considered as insufficient and they were corrected as necessary until LP on
was observed; (7), closure with clips at the entry site was performed (Fig. 1).

**Follow-up**

Twenty-four hours after POEM, upper GI endoscopy was performed to rule out adverse events. A proton pump inhibitor (PPI) was administered for four weeks. Diet progressed from a liquid diet up to a normal one over the following 3 weeks. Follow-up continued for 6 months, with HRM, GI endoscopy, pHmetry, TBE, reflux questionnaires, and Eckardt scores evaluated at 3 and 6 months. Success was defined as an integrated relaxation pressure (IRP) < 15 mmHg, Eckardt score < 3, and TBE demonstrating adequate passage of contrast (≥ 80% at 5 minutes) 3 and 6 months postoperatively.

**G-POEM**

**Patients**

Gastroparesis was diagnosed based on clinical evaluations and scintigraphy. Severe refractory gastroparesis was based on the presence of delayed gastric emptying-related symptoms, including nausea, retching, vomiting, abdominal pain, post-prandial fullness, early satiety and/or bloating. Patients who had failure or recurrence after receiving optimal pharmacological therapies and a Gastroparesis Cardinal Symptom Index (GCSI) score > 2.3 (score that has been validated as severe when greater than 2.3) [22] with a retention percentage at 4 hours (RP4H) in GES > 10% and a mean half emptying time (MHET) > 150 min, were also diagnosed with severe refractory gastroparesis. Efficacy was evaluated based on a reduction in the self-reported gastroparetic symptoms of the patients; the absence of recurrent hospitalizations and the proportion of patients with a decrease in GCSI score < 2.3, RP4H < 10% and MHET < 150 min. Adverse events in POEM and G-POEM were graded according to the American Society for Gastrointestinal Endoscopy Lexicon [23].
Procedure

Procedures were performed in the endoscopic unit under general anesthesia. Forty-eight hours before the procedure, all patients were administered a liquid diet and antibiotic prophylaxis. Endoscopic instruments were the same as in POEM patients, including the LP. The G-POEM procedure was based on Khashab’s technique [24]. The technique was performed based on the following protocol: (1), revision and cleaning of the stomach were performed; (2), injection and incision were performed 5 cm before the pylorus for submucosal bleb creation using a combination of saline solution with 0.5% methylene blue. A longitudinal 1.5 cm incision was also performed. (3), a submucosal tunnel was performed in pyloric direction until PMR was identified. If submucosal tunnel orientation was lost during this step, LP was used and was inserted throughout the mouth, grasped with biopsy forceps and placed intraluminally into the duodenal bulb in order to guide submucosal tunnel creation and PMR identification (4), myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum was performed; the incision was 3–4 cm in length and deep up to the serosa. LP was used for myotomy confirmation in all cases. (5), the incision was closed using the over the scope clips (OTSC) type A (OVESCO Endoscopy, AG, Tübingen, Germany) or hemoclips (Fig. 2).

Follow-up

Patients were admitted to the hospital after the procedure and given intravenous antibiotics. An upper GI series was obtained the following day to ensure leakage was not present. Diet progressed from a liquid diet to a normal diet over the next week. PPI was administered for 4 weeks. Both GCSI and GES, were performed 3 and 6 months postoperatively.

Statistical analyses
Sample size was calculated based on an assumption that there would be at least 90% of efficacy in the completion of third-space procedures when LP is used, with a significance level of 0.05 (type I error of 5%) and a beta of 0.20 (type II error of 20%). Using an online statistically validated program for sample size calculation (EpiInfo, USA), we calculated a minimum of 25 patients for POEM and G-POEM procedures. Quantitative data were expressed as mean (standard deviation [SD]) or median with interquartile range (IQR); qualitative data were expressed as frequencies and percentages. Bivariate comparisons were done using the Friedman test, chi-squared test and a one-way analysis of variance, as appropriate. P < 0.05 was considered to be statistically significant. SPSS v.23.0 (IBM, Chicago, Illinois, USA) was used for all statistical analyses.

Results

There were 70 third-space procedures performed between December 2016 and January 2019 (42 POEM and 28 G-POEM).

POEM

Baseline characteristics

Forty-two patients were included with a mean age of 46.7±14.3 years and 18 (42.9%) were male. Esophagus type grade II (16 [38%]) and achalasia subtype II (20 [47.6%]) were the most common. Thirty-two (76.2%) were naïve, while 10 (23.8%) were previously treated, (60% had undergone LHM, 20% botulinum toxin injection, and 20% pneumatic dilation). No Chagas disease was found.

Procedure

The median total POEM time was 50 minutes (IQR 38-71). The mean tunnel and myotomy lengths were 12.9±3.6 cm and 10.5±3.1 cm, respectively. The most common mild adverse event was minor bleeding in 2 cases (4.7%), and the median length of stay
(LOS) was 3 days (IQR 1-4).

**Efficacy**

Clinical response was observed in all cases at the 6-month follow-up. The Eckardt score decreased from 9 to 1 at the 3-month follow-up ($P<0.001$) and did not change at the 6-month follow-up ($P<0.001$). The IRP decreased from $27.3\pm10.8$ mmHg to $9.8\pm3.8$ mmHg at the 3-month follow-up ($P<0.001$) and $9.5\pm4.1$ mmHg at the 6-month follow-up ($P<0.001$); TBE showed emptying of <50% in 100% of patients to emptying of >50% in 100% ($p>0.001$) after 6 months. Furthermore, 57% presented positive pHmetry, 15% had esophagitis and 12% had clinical symptoms of reflux disease *(Table 1).*

**G-POEM**

**Baseline characteristics**

Twenty-eight patients with a mean age of $43.7\pm10.1$ years were included and 13 were male (46.4%). The most common etiology was diabetes in 12 (42.9%) and the mean duration of disease before G-POEM was $22.2\pm5.5$ months. The most predominant symptoms and previous therapy were: nausea and vomiting in 15 (53.5%), and medical therapy in 22 (78.7%), respectively. The median number of hospitalizations preoperatively was 2 (IQR 2-5).

**Procedure**

The median total G-POEM time was 60 minutes (IQR 48-77). The mean tunnel and myotomy lengths were $5.2\pm0.96$ cm and $3.2\pm0.82$ cm, respectively. The most common mild adverse event was capnoperitoneum in 2 patients (7.1%); it required abdominal decompression with a Veress needle and 1 mucosal tear 24 hrs after procedure and was solve endoscopically with clips. The median LOS was 2 days (IQR 1-6).

**Efficacy**
The GSCI score decreased from 3.5±0.64 points to 1.8±0.61 after 3 months (P<0.001), and 1.2±0.43 after 6 months (P<0.001). GES test showed a decrease in RP4H from 35.3±11.6 to 11.1±4.2 after 3 months (P<0.001), and 9.3±3.2 after 6 months (P<0.001). The half-emptying time improved from 260.2±66.9 min to 165.9±31.2 min after 3 months (P<0.001), and 152.7±23.1 min after 6 months (P<0.001). Clinical response was observed in 24 patients (85.7%) at the 6-month evaluation. Resolution of the predominant symptoms were as follows: resolved in 16 (57.1%), 18 (64.3%) and 9 (32.1%); improved in 10 (35.8%), 5 (17.8%) and 11 (39.2%); not changed in 1 (3.6%), 3 (17.8%) and 7 (25%); and worsened in 1 (3.6%), 2 (7.2%) and 1 (3.6%), for nausea/vomiting, abdominal pain and gastric fullness, respectively. GES was normalized in 17 (60.7%) and partially improved in 8 (28.5%) of patients at the 6-month evaluation. (Table 2).

**LED probe**

The median placement time for POEM and G-POEM were 5 (IQR 4-6) and 6 (IQR 5-7) min, respectively. All probes were successfully placed without adverse events and no adverse events or technical failures were observed after procedures secondary to their use. There was no damage to the submucosal space or at the intraluminal mucosal level. In general, LP use helped to complete adequately POEM and G-POEM in 11/70 (15.7%) of cases. After initial classic POEM procedure, LP on was placed and not observed in 6/42(14.2%) of cases. Therefore, submucosal tunnel and myotomy were extended up to an adequate LP confirmation. In G-POEM cases, inadequate submucosal direction was found in 5/28(17.8%) of cases and LP use helped to correct it and confirm myotomy of the PMR in all cases. (Video 2)

**Discussion**

In this study we evaluated the feasibility of using a new device, the LP, and confirmed its
safe and effective use in clinical practice when performing third-space procedures (POEM and G-POEM).

Third-space endoscopy was first described by Sumiyama et al [25]; it was first used in animals in 2007, and then used in humans. It is based on the creation of a submucosal tunnel to perform surgical procedures with confirmed safety and efficacy. It transforms the concept of endoluminal endoscopy to intramural, making many diseases that previously would have been treated by open or laparoscopic surgery endoscopically curable [1, 4].

The lumen is considered as the first space, while the peritoneum is considered the second space and the intentionally-created tunnel is the third space (space between the mucosa and muscularis propria) [2–4]. Different disorders have been addressed by this technique, including Zenker’s diverticulum, myotomy for achalasia, gastroparesis, Hirschsprung’s disease, removal of tumors arising from the muscularis propria and beyond, and stricture treatment [1, 2, 8]. Among them, achalasia and gastroparesis are the most prevalent diseases treated by this technique. However, “difficult”, “incomplete”, or even “not possible” tunnel creation or myotomy have been described and are associated with certain complexity factors such as end-stage disease (POEM)[5], previously-treated cases (POEM and G-POEM)[4, 8, 24], inability to identify EGJ (POEM)[6–8], PMR (G-POEM)[9], high submucosal fibrosis (POEM and G-POEM)[2–4, 6–8], lack of experience (POEM and G-POEM) [2, 3, 6], or anatomical factors (POEM)[1, 4, 9, 10]. These factors result in a failed procedure, even if the endoscopist believes that the procedure was successful [1, 3]. If the tunnel is too short, the procedure is ineffective; if the length of the myotomy is too long, there is a higher risk of adverse events, including perforation or bleeding[3, 12]. Currently, there are several endoscopic landmarks, such as palisading vessels at the EGJ and the circular bundle of LES fibers in POEM (difficult use and inaccurate), or the
continuous insertion and extraction of the endoscope from the tunnel, that are used to identify the PMR, which is technically challenging. A second endoscope (POEM and G-POEM) [12, 13] and fluoroscopy (G-POEM)[9, 11] are used in attempt to overcome these problems; however, these methods are costly or are unavailable. Therefore, we decided to explore a new alternative to overcome these problems when performing third-space endoscopy.

The use of lighting devices has been explored in medicine during years. In colorectal and gynecological surgeries, for example, iatrogenic ureteric injury is a serious complication with a variable incidence between 0.7–10% [14]. The identification of ureters is challenging and the optional double J stent placement is invasive and associated with serious adverse events [15]; however, the use of fluorescence and lighted ureteral stents has overcome these problems. LED technology was invented in 1907 by H. J. Round but was commercially available in 1962 in electrical components. Modern LED technology with more practicality was used after 2010[17]; uses in medicine are confirmed in ophthalmologic procedures where improved illumination for vitrectomy has been observed [16]. LED has advantages over incandescent light sources. It provides lower energy consumption, a longer lifetime, smaller size, faster switching, a better spectrum of light and intensity (emitting more lumens per watt compared with light bulbs), and cool light that radiates minimal heat. It is safe because mercury or other hazardous metals are not contained within them [16, 17].

Because of safety and efficiency, we decided to use a white LED-probe and orally insert it into a conventional 127 cm x20 Fr nasogastric feeding tube. Excellent visualization was obtained with the 112 lm/m of the probe; this was enough to be visualized under the submucosal tunnel or over the intraluminal space when inserted into the tunnel. We didn’t have technical problems during assembly or during procedures. Safety and efficacy of this
device was confirmed with a median insertion time of 5 minutes (4-6) for POEM and 6 (5-7) for G-POEM and didn’t compromise the total procedural times, being similar to those observed in previous studies [5-7, 10, 11, 21, 24].

POEM was performed as described by other groups [5, 6, 21], with similar demographic characteristics. However, in our cohort 23.8% were previously treated and 38% grade III and IV. Being the subgroups theoretically more difficult to treat; therefore, with the greatest benefit if LP is used. Nonetheless, POEM was completed in 100% of cases and the mean myotomy length was 10.5±3.1 cm, which is similar to the length of 9.4±3.1 cm obtained in other studies [6]. Grimes et al[13] compared double-scope vs conventional POEM in a clinical trial that included 50 patients per group. No differences in technical (98% vs 100%) or clinical success (93% vs 97%) was found; but, with a 34% longer myotomy and 17 min increase in procedural times for double-scope group. In our study, the LP was 6 mm in diameter, which is similar to the length of the neonatal endoscope used in Grimes’ study. However, our LP system was advantageous in terms of cost (10 dls per LP), and placement time (5 min vs 17 min). We confirmed an adequate myotomy in all cases including 6 patients (14.2%) who were considered as difficult (4 grade IV, 1 grade III and 1 pneumatic dilation), in whom classic POEM didn’t complete myotomy and were benefited from the LP use, avoiding potential adverse events or risk of uncomplete procedure. Additionally, no other endoscopy tower was needed (saving costs and space in the endoscopy room). Finally, clinical outcomes and the occurrence of reflux disease was similar to those of other studies [5-8, 12, 13, 21].

We performed the G-POEM and LP placement in all cases. Demographic characteristics were similar to other groups [8-11, 24]. The pylorus was previously manipulated in 21.4% of cases (botulinum toxin injection and transpyloric stent), potentially difficult cases. However, median G-POEM time (60 min) is similar to other groups [1, 9-12, 24]. Xue H et
al [9], compared the use of fluoroscopy-guided G-POEM vs conventional G-POEM procedure in 14 patients; all procedures achieved technical success, the PMR was identified in all 7 patients of the fluoroscopy-guided group, and only in 4 (57.1%) from the control (P < 0.03). However, this was not clinically expressed, with a non-statistically significant difference between GCSI and GES. In our group, LP provided a better orientation towards PMR identification and myotomy confirmation in all cases. Including 5/28 patients where the endoscopist was “lost”, during tunnel creation and PMR was not identified, the LP allowed the completion of G-POEM procedures, representing a 17.8% of benefit in them. However, besides the G-POEM outcomes were slightly better in our study, when compared with other centers, with a general clinical success (85.7% vs 69–81%) in GCSI and GES (89.2% vs 69–84.2%) at 6-month evaluations, we can’t assume that this could be explained because of the 100% PMR identification (similar to the fluoroscopy-guided group from Xue’s study). However, as stated by other authors, different gastroparesis subtypes with their corresponding physiopathology could explain the real heterogeneous mid-term results more than the simple direct effect of the PMR cutting, inclusive with LP guidance, as in our patients [1–4, 9–11, 24].

The strengths of our study include the use of LP in the two most common and important third-space procedures, the sample size that was reached in both and calculated for statistical significance, adequate and strict procedural and follow-up protocols, technical confirmation of all steps in all cases, and excellent safety without adverse events associated with LP use. Our study also has limitations that should be addressed. First, LP is not yet commercially available. Second, PL has to be made before each procedure by the medical doctor, which could be time-consuming. Third, different LED and nasogastric feeding tube brands exist around the world, which limits the availability of the system we used. Fourth, only POEM and G-POEM cases were included; pediatric and other third-space
procedures were not included. However, we think that LP is a useful device for POEM and G-POEM procedures because of its simplicity, innovation, low costs, safety and the ability to make difficult procedures potentially easier.

Conclusion

In conclusion, we have confirmed the feasibility of using LP in third-space endoscopy as a new alternative to perform POEM or G-POEM cases, being specifically useful when classic anatomical landmarks are not completely reliable, in difficult cases, low-volume POEM and G-POEM centers, limited third-space procedures experience and when no other confirming methods are available. However, the real clinical relevance of LP use must be confirmed with longer evaluations and comparative studies. Commercialization and evaluation in other third-space procedures are necessary to elucidate potential advantages of the LP system.

Acronyms And Abbreviations

LP = LED-probe
POEM = Peroral endoscopic myotomy
G-POEM = Gastric peroral endoscopic myotomy
GES = gastric emptying scintigraphy
IQR = interquartile range
IRP = Integrated relaxation pressure
EGJ = Esophagogastric junction
PMR = pyloric muscle ring
LED = Light-emitting diode
HRM = High resolution manometry
Upper GI = Upper gastrointestinal
CT = Computed tomography
TBE = Timed barium esophagogram
PPI = Proton pump inhibitor
GCSI = Gastroparesis Cardinal Symptom Index
RP4H = Retention Percentage 4 hours
OTSC = Over the scope clip
SD = Standard deviation

Declarations

1.- Ethics Approval and consent to participate

This protocol was approved by the Local Ethics Committee named: “Comité Local de Investigación y Ética en Investigación en Salud 3601 con número de registro 13 CI 09 015 184 ante la COFEPRIS” which belongs to “Hospital de especialidades Dr. Bernardo Sepúlveda Gutierrez, Centro Médico Nacional Siglo XXI. Del Instituto Mexicano del Seguro Social”. They approved our protocol with the number: R-2016-3601-192; and registration number: 2016-CMN675). Written Informed consent was obtained from all patients.

2.- Consent for publication

Not applicable

3.- Availability of data and materials

All data generated or analyzed during this study are included in this published article [we added spv files as supplementary files].

4.- Competing interests

OVHM, RAZM, OMSP, RAGA and LFGC, declare not to have any competing interests.

5.- Funding

The authors declare not to have any funding source for the development of the present study
6.- Authors contributions:

1.-OVHM: Conception of LP protocol and idea, creation of manuscript, POEM and G-POEM cases, revision of final manuscript

2.-RAZM: Analysis and interpretation of the data, figures and tables creation.

3.-OMSP: Acquisition of data and design, statistical analyses, POEM and G-POEM cases.

4.-RAGA: Cases management and follow-up, analysis and interpretation of data.

5.-LFGC: POEM and G-POEM cases management and follow-up

All authors have read and approved the present manuscript

7.- Acknowledgements

Not applicable

References

1.- Manolakis AC, Inoue H, Ueno A, Shimamura Y. (2019) 2007-2019: a “Third”- Space Odyssey in the Endoscopic Management of Gastrointestinal Tract Diseases. Curr Treat Options Gastroenterol 17:202-220.

2.- Nabi Z, Nageshwar R and Ramchandani M. (2018) Recent advances in Third-Space Endoscopy. Gastroenterol Hepatol 14:224-232.

3.- Eleftheriadis N, Inoue H, Ikeda H, Onimaru M, Maselli R, Santi G (2016) Submucosal tunnel endoscopy: Peroral endoscopic myotomy and peroral endoscopic tumor resection. World J Gastrointest Endosc 8:86-103.

4.- Kobara H, Mori H, Rafiq K, MasaKI T. (2014) Submucosal tunneling techniques: current perspectives. Clin Exp Gastroenterol 5:67-74.

5.- Li QL, Wu QN, Zhang XC, Xu MD, Zhang W, Chen SY, Zhong YS, Zhang YQ, Chen WF, Qin WZ, Hu JW, Cai MY, Yao LQ, Zhou PH. (2018) Outcomes of per-oral endoscopic myotomy for treatment of esophageal achalasia with a median follow-up of 49 months. Gastrointest Endosc 87:1405-1412.
6.- Akintoye E, Kumar N, Obatian I, Alayo QA, Thompson CC. (2016) Peroral endoscopic myotomy: a meta-analysis. Endoscopy 48:1059-1068.
7.- Werner YB, Rösch T. (2016) POEM and submucosal tunneling. Curr Treat Options Gastroenterol 14:163-167.
8.- Parikh MP, Gupta NM, Sanaka MR. (2019) Esophageal Third Space Endoscopy: Recent Advances. Curr Treat Options Gastroenterol 17:63-75
9.- Xue HB, Fan HZ, Meng XM, Cristofaro S, Mekaroonkamol P, Dacha S, Li LY, Fu XL, Zhan SH, Cai Q. (2017) Fluoroscopy-guided gastric peroral endoscopic pyloromyotomy (G-POEM): a more reliable and efficient method for treatment of refractory gastroparesis. Surg Endosc 31:4617-4624
10.- Shlomovitz E, Pescarus R, Cassera MA, Sharata AM, Reavis KM, Dunst CM, Swanström LL. (2015) Early human experience with per-oral endoscopic pyloromyotomy (POP). Surg Endosc 29:543-551.
11.- Koul A, Dacha S, Mekaroonkamol P, Li X, Li L, Shahnazav N, Keilin S, Willingham FF, Christie J, Cai Q. (2018) Fluoroscopic gastric peroral endoscopic myotomy (G-POEM) in patients with failed gastric electrical stimulator. Gastroenterol Rep 6:122-126.
12.- Hong HJ, Song QW, Ko WJ, Jim MH, Hahm KB, Hong SP, Cho JY. (2016) Double-Scope Peroral Endoscopic Myotomy (POEM) for Esophageal Achalasia: The First Trial of a New Double-Scope POEM. Clin Endosc 49:383-386.
13.- Grimes KL, Inoue H, Onimaru M, Ikeda H, Tansawet A, Bechara R, Tanaka S. (2016) Double-scope per oral endoscopic myotomy (POEM): a prospective randomized trial. Surg Endosc 30:1344-1351.
14.- Boyan WP jr, Lavy D, Dinallo A, Otero J, Roding A, Hanos D, Dressner R, Arvanitis M. (2017) Lighted ureteral stents in laparoscopic colorectal surgery; a five-year experience. Ann Transl Med 5:44-48.
15.- Hamilton AER, Westwood DA, Cuda TJ, Stevenson ARL. (2018) Identification of the ureter during robotic colorectal surgery using lighted stents – a video vignette. Colorectal Dis 20:163-164.

16.- Koelbl PS, Lingenfelder C, Spraul CW, Kampmeier J, Koch FH, Kim YK, Hessling M. (2019) An intraocular micro light-emitting diode device for endo-illumination during pars plana vitrectomy. Eur J Ophthalmol 29:75-81.

17.- Pan JW, Su YC, Chen YS. Secondary optical element design for intracorporeal LED illumination system. Opt Lett 2014;39:224-227.

18.- Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE. (2015) The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 27:160-174.

19.- Rezende JM. (1982) Classificação radiológica do megaesôfago. Rev Goiana Med 28:187-191.

20.- Eckardt VM, Aignherr C, Bernhard G. (1992) Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology 103:1732-1738.

21.- Inoue H, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki M, Satodate H, Odaka N, Itoh H, Kudo S. (2010) Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 42:265-271.

22.- Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stangellini V, Talley NJ, Tack J. (2003) Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther 18:141-150.

23.- Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcak A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. (2010) A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 71:446-54.
24.- Khashab MA, Steint E, Clarke JO, Saxena P, Kumbhari V, Chander Roland B, Kaloo AN, Stavropoulos S, Pasricha P, Inoue H. (2013) Gastric peroral endoscopic myotomy for refractory gastroparesis: first human endoscopic pyloromyotomy (with video). Gastrointest Endosc 78:764-768

25.- Sumiyama K, Gostout CJ, Rajan E, Bakken TA, Knipschield MA, Marler RJ. (2007) Submucosal endoscopy with mucosal flap safety valve. Gastrointest Endosc 65:688-694

Tables

**Table 1.- Characteristics of the 42 POEM procedures performed with LED probe**
### Patients

| N=42 | Value |
|------|-------|
| **Age, mean (SD), years** | 46.7±14.3 |
| **Sex, male, n (%)** | 18 (42.9%) |
| **Type of esophagus, n (%)** | |
| Normal | 2 (5%) |
| Grade I | 8 (19%) |
| Grade II | 16 (38%) |
| Grade III | 8 (19%) |
| Grade IV | 8 (19%) |
| **Previous treatments, n (%)** | |
| Treatment naïve | 32 (76.2%) |
| Previously treated | 10 (23.8%) |
| +Post-LHM | 6 (60%) |
| +Botulinum toxin injection | 2 (20%) |
| +Pneumatic dilation | 2 (20%) |
| **Achalasia subtype, n (%)** | |
| Type I | 11 (26.2%) |
| Type II | 20 (47.6%) |
| Type III | 11 (26.2%) |

### PROCEDURE

|   | Value |
|---|-------|
| **Tunnel length, mean (SD), cm** | 12.9±3.6 |
| **Myotomy length, mean (SD) cm** | 10.5±3.1 |
| **LP placement time, median (IQR), min** | 5 (4-6) |
| **Patients with inadequate myotomy after initial classic POEM that benefited from LP use (difficult cases), n (%)** | 6 (14.2%) |
| **Total POEM time, median (IQR), min** | 50 (38-71) |
| **Adverse Events, n (%)** | |
| Minor bleeding | 4 (9.4%) |
| Pneumoperitoneum | 2 (4.7%) |

### POEM OUTCOMES

|   | PRE-POEM | POST-POEM 3m | POST-POEM 6m | P value |
|---|----------|-------------|-------------|---------|
| **Eckardt score, median (IQR), points** | 9 (6-12) | 1 (0-3) | 1 (0-3) | <0.00 |
| **IRP pressure, mean (SD), mmHg** | 27.3±10.8 | 9.8±3.8 | 9.5±4.1 | <0.00 |
| **TBE** | | | | <0.00 |
| <50% | 100% | 0% | 0% | |
| 50-80% | 0% | 14% | 9.5% | |
| >80% | 0% | 86% | 90.5% | |

SD, standard deviation; IQR, interquartile range; POEM, peroral endoscopic myotomy; LP, led-probe; LHM, laparoscopic Heller myotomy.

1 Friedman test
ANOVA test

$\chi^2$ test

Table 2.- Characteristics of the 28 G-POEM procedures performed with LED probe
| Patients N=28 | Value |
|--------------|-------|
| Age, mean (SD), years | 43.7±10.1 |
| Sex, male, n (%) | 13 (46.4) |
| Etiology, n (%) | |
| Diabetic | |
| Idiopathic | |
| Postsurgical | |
| Duration of disease before G-POEM, mean (SD), months | |
| 12 (42.9%) | |
| 11 (39.2%) | |
| 5 (17.9%) | |
| Predominant symptoms, n (%) | |
| Nausea/vomiting | 22.2±5.5 |
| Abdominal pain | |
| Gastric fullness | |
| Previous therapy, n (%) | |
| Medical treatment | 15 (53.5%) |
| Botulinum toxin injection | 8 (28.6%) |
| Transpyloric stenting | 5 (17.9%) |
| PROCEDURE | |
| Tunnel length, mean (SD), cm | |
| Myotomy length, mean (SD), cm | 22 (78.7%) |
| LP placement time, median (IQR), min | 5 (17.8%) |
| Patients with inadequate submucosal tunnel direction after initial classic G-POEM procedure that benefited from LP use, n (%) | 5.2±0.96 |
| Total G-POEM time, median (IQR), min | 3.2±0.82 |
| Adverse Events, n (%) | |
| Capnoperitoneum | 6 (5-7) |
| Mucosal tear | 5 (17.8%) |
| Prepyloric ulcer | |
| G-POEM OUTCOMES | PRE-GPOEM | POST-GPOEM 3m | POST-GPOEM 6m | P value |
| GSCI score, mean (SD), points | 3.5±0.64 | 1.8±0.61 | 1.2±0.43 | <0.001 |
| RP4H, mean (SD), percentage | 35.3±11.6 | 11.1±4.2 | 9.3±3.2 | <0.001 |
| MHET, mean (SD), minutes | 260.2±66.9 | 165.9±31.2 | 152.7±23.1 | <0.001 |

SD, standard deviation; IQR, interquartile range; G-POEM, gastric peroral endoscopic myotomy; LP, led-probe; GSCI, gastroparesis cardinal symptoms index; RPH4, retention percentage 4 hours; MHET, mean half emptying time.

1 ANOVA test
Figures

Figure 1

Animation and endoscopic image of POEM procedure guided and confirmed with LP. A) LP is inserted into the submucosal tunnel. B) Intraluminal view of LP while switched on C) Endoscopic retroflex view at esophagogastric junction for confirmation of myotomy before entry site closure. LP= Led-probe, EGJ= Esophagogastric junction.
Figure 2

Animation and endoscopic image of G-POEM procedure guided and confirmed with LP. A) LP is inserted intraluminally into the duodenal bulb. B) Endoscopic view of LP throughout the submucosal space. Gastric and duodenal LED lights are observed with PMR at the bottom. C) Myotomy is performed with LP guidance.

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

Video 2 send.mov
Video 1 LED Probe construction1.mov
LEDPOEM.xls
LEDGPOEM.xls